Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2012

View Archived Issues

Otsuka Pharmaceutical reports new candidate cancer therapies

Novel inhibitors of diacylglycerol O-acyltransferase 1 presented

Abbott designs novel focal adhesion kinase 1 inhibitors

AstraZeneca scientists discover novel plasminogen inhibitors

New sodium channel antagonists described

Hepatitis C vaccine shows promise in proof-of-concept trial

BRISK PS trial compares brivanib to placebo in liver cancer

Phase II data presented on ACE-031 in boys with Duchenne's muscular dystrophy

Doxapram enantiomer retains respiratory stimulant properties without adverse effects

Novel multikinase inhibitor is active in FLT3-dependent leukemia cells

Isis begins phase II ISIS-APOCIIIRx study

Genfit reports on GFT-505 study in NAFLD/NASH

Gentium receives day 180 list from EMA for defibrotide MAA

Sato Pharmaceutical set to launch anesthetic cream in Japan

FDA approves expanded dose range for schizophrenia drug

Pfizer stops phase III study of Lyrica

Phase III study of hydroxychloroquine begins in Japan

Abbott to acquire melanocortin receptor agonist

MediGene receives final milestone payment for Eligard

Pfizer offers overview of first quarter 2012

Exelixis expands cabozantinib development program

Oncolytics Biotech enters into agreement for phase II Reolysin study

NIH launches program providing researchers access to industry compounds

Phase IIIb trial of Lyrica does not meet primary endpoint

Roche terminates development of antidyslipidemia drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...